← Back to Search

Cannabinoid

Cannabidiol for Parkinson's Disease

Phase 2
Recruiting
Led By Maureen Leehey
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline; at the end of 2.5 mg/kg/day; and every 3-5 days at each dose level, through 3 weeks.
Awards & highlights

Study Summary

This study is evaluating whether cannabidiol may have positive impacts for individuals with Parkinson's disease.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline; at the end of 2.5 mg/kg/day; and every 3-5 days at each dose level, through 3 weeks.
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline; at the end of 2.5 mg/kg/day; and every 3-5 days at each dose level, through 3 weeks. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Movement Disorders Society-Unified Parkinson's disease rating scale (MDS-UPDRS) Part III (motor examination) scores
Secondary outcome measures
Change in Anxiety Short Form response
Change in Axial sub scores in MDS UPDRS
Change in Bradykinesia sub scores in MDS UPDRS
+53 more

Side effects data

From 2022 Phase 2 & 3 trial • 90 Patients • NCT04387617
38%
Tiredness
24%
Drowsiness
24%
Poor sleep
22%
Constipation
18%
Poor Appetite
16%
Dizziness
9%
Headache
7%
Diarrhea
7%
Nausea
4%
Itching
100%
80%
60%
40%
20%
0%
Study treatment Arm
CBD Oil Group
Control Group

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CBD Cannabis extract oral solutionExperimental Treatment1 Intervention
Cannabidiol (CBD) Cannabis extract oral solution
Group II: placeboPlacebo Group1 Intervention
Placebo oral solution
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cannabidiol
2021
Completed Phase 3
~1010

Find a Location

Who is running the clinical trial?

Colorado Department of Public Health and EnvironmentOTHER_GOV
10 Previous Clinical Trials
9,489 Total Patients Enrolled
University of Colorado, DenverLead Sponsor
1,732 Previous Clinical Trials
2,143,508 Total Patients Enrolled
Maureen LeeheyPrincipal InvestigatorUniversity of Colorado School of Medicine

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease
2018. "A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03582137.
All > Cbd > Parkinson
~11 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top